Galmed Pharmaceuticals (GLMD) AI Stock Analysis

• Market Cap: $4.13M
• Dividend Yield: N/A
• Average Volume (3M): 313.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.42
• Revenue Growth: N/A
• EPS Growth: 71.41%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.62
• Shares Outstanding: 2,258,034
• 10 Day Avg. Volume: 350,398
• 30 Day Avg. Volume: 313,086
• PEG Ratio: 0.86
• Price to Book (P/B): 0.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.78
• Enterprise Value/Market Cap: -0.16
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 8.19
• Enterprise Value/Ebitda: 0.03
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 28 Underperform
• Price Target: ―

Galmed Pharmaceuticals faces significant financial challenges, with no revenue and continuous losses, which heavily impact its stock score. Poor technical indicators and negative valuation metrics further weigh down the score. The strong equity position offers some support but is overshadowed by the lack of operational efficiency and profitability.

Positive Factors

Market Opportunities

Targeting international markets where semaglutide is not meaningfully patent-protected presents significant market opportunities for Galmed.

Partnerships

Galmed has partnered with Virginia Commonwealth University to evaluate Aramchol’s potential in oncology indications.

Negative Factors

Clinical Trials

The company halted the Phase 3 trial for Aramchol meglumine due to financial and enrollment issues.

Strategic Uncertainty

Galmed's strategic positioning and path forward remains unclear.

Galmed Pharmaceuticals Business Overview & Revenue Model

Company Description

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

How the Company Makes Money

Galmed Pharmaceuticals makes money primarily through the development and potential commercialization of its lead product candidate, Aramchol. As a clinical-stage company, Galmed does not currently generate product revenues. Instead, the company relies on funding from public and private investors to finance its research and development activities. In the future, Galmed aims to generate revenue through the successful commercialization of Aramchol, which could include sales, licensing agreements, or partnerships with larger pharmaceutical companies. Collaborations and partnerships could provide upfront payments, milestone payments, and royalties based on sales performance once Aramchol or any other product candidates receive regulatory approval and are brought to market.

Galmed Pharmaceuticals Financial Statement Overview

Summary

Galmed Pharmaceuticals exhibits a challenging financial outlook. The company reports zero revenue, leading to increasing net losses and negative profit margins. While the balance sheet shows no debt and strong equity, the negative cash flow and reliance on equity financing pose significant risks to sustainability.

Income Statement

Galmed Pharmaceuticals has consistently reported zero revenue, which severely impacts its profitability. The company has faced increasing net losses over the years, with a significant negative net profit margin. Both EBIT and EBITDA margins are deeply negative, reflecting poor operational performance.

Balance Sheet

The company maintains a strong equity position with no debt, resulting in a favorable debt-to-equity ratio. However, the absence of revenue and continuous losses undermine the return on equity, which remains negative. The equity ratio is high, indicating reliance on equity financing.

Cash Flow

Galmed Pharmaceuticals shows a negative free cash flow, consistently higher operating cash outflows than net income, indicating operational inefficiencies. The company relies heavily on external financing, as seen in the positive financing cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-83.00K	-31.00K	-35.00K	-42.00K	-39.00K
EBITDA	-7.42M	-6.87M	-17.62M	-32.84M	-30.17M
Net Income	-7.52M	-6.91M	-18.57M	-31.95M	-27.61M
Balance Sheet
Total Assets	18.50M	16.63M	16.56M	36.60M	52.38M
Cash, Cash Equivalents and Short-Term Investments	15.33M	12.64M	13.79M	34.81M	50.89M
Total Debt	0.00	41.00K	44.00K	229.00K	216.00K
Total Liabilities	2.17M	2.75M	3.14M	6.11M	8.23M
Stockholders Equity	16.33M	13.88M	13.42M	30.50M	44.15M
Cash Flow
Free Cash Flow	-5.88M	-6.14M	-18.50M	-32.90M	-26.33M
Operating Cash Flow	-5.88M	-6.14M	-18.50M	-32.89M	-26.29M
Investing Cash Flow	-1.11M	800.00K	17.56M	11.46M	16.54M
Financing Cash Flow	8.79M	6.18M	70.00K	17.37M	768.00K

Galmed Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GLMD, the sentiment is Positive. The current price of 2.09 is above the 20-day moving average (MA) of 1.77, above the 50-day MA of 1.53, and below the 200-day MA of 2.68, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 72.07 is Negative, neither overbought nor oversold. The STOCH value of 68.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GLMD.

Galmed Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.45B	0.30	-61.93%	2.28%	16.62%	1.04%
MTNB	45 Neutral	$4.68M	―	-192.85%	―	-100.00%	5.43%
INM	44 Neutral	$3.30M	―	-91.71%	―	-11.94%	56.72%
GLTO	29 Underperform	$4.30M	―	-91.32%	―	―	48.81%
GLMD	28 Underperform	$4.13M	―	-49.58%	―	―	71.41%
HEPA		$790.29K	―	-288.06%	―	―	―
QNRX	25 Underperform	$5.22M	―	-138.80%	―	―	42.26%